Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan

被引：0
|
作者：
Ben Johnson
Edward Chia-Cheng Lai
Huang-tz Ou
Hong Li
Björn Stollenwerk
机构：
[1] Amgen Ltd,Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine
[2] National Cheng Kung University,undefined
[3] Amgen Asia Holding Limited,undefined
[4] Amgen GmbH,undefined
来源：
Archives of Osteoporosis | 2021年 / 16卷
关键词：
Denosumab; Real-world; Cost-effectiveness; Osteoporosis; Postmenopausal; Taiwan;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan
    Johnson, Ben
    Lai, Edward Chia-Cheng
    Ou, Huang-tz
    Li, Hong
    Stollenwerk, Bjorn
    [J]. ARCHIVES OF OSTEOPOROSIS, 2021, 16 (01)
  • [2] Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis
    Jonsson, B.
    Strom, O.
    Eisman, J. A.
    Papaioannou, A.
    Siris, E. S.
    Tosteson, A.
    Kanis, J. A.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2011, 22 (03) : 967 - 982
  • [3] Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis
    B. Jönsson
    O. Ström
    J. A. Eisman
    A. Papaioannou
    E. S. Siris
    A. Tosteson
    J. A. Kanis
    [J]. Osteoporosis International, 2011, 22 : 967 - 982
  • [4] Comment on: cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis
    B. Jönsson
    O. Ström
    J. A. Eisman
    A. Papaioannou
    E. S. Siris
    A. Tosteson
    J. A. Kanis
    [J]. Osteoporosis International, 2012, 23 : 2063 - 2065
  • [5] Cost-effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in Malaysia
    Choo, Y. W.
    Mohd Tahir, N. A.
    Mohamed Said, M. S.
    Li, S. C.
    Makmor Bakry, M.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2022, 33 (09) : 1909 - 1923
  • [6] COST-EFFECTIVENESS OF DENOSUMAB IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS IN SCOTLAND
    Davies, A.
    Compston, J.
    Ferguson, S.
    McClosky, E.
    Shearer, A.
    Taylor, A.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A310 - A310
  • [7] Comment on: cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis
    Jonsson, B.
    Stroem, O.
    Eisman, J. A.
    Papaioannou, A.
    Siris, E. S.
    Tosteson, A.
    Kanis, J. A.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2012, 23 (07) : 2063 - 2065
  • [8] Cost-effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in Malaysia
    Y. W. Choo
    N. A. Mohd Tahir
    M. S. Mohamed Said
    S. C. Li
    M. Makmor Bakry
    [J]. Osteoporosis International, 2022, 33 : 1909 - 1923
  • [9] COST-EFFECTIVENESS COMPARISON OF DENOSUMAB AND ZOLEDRONIC ACID IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
    Ding, Y.
    Hay, J.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A47 - A47
  • [10] Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women
    Hiligsmann, Mickael
    Boonen, Annelies
    Dirksen, Carmen D.
    Ben Sedrine, Wafa
    Reginster, Jean-Yves
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2013, 13 (01) : 19 - 28
12345